These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30822708)

  • 1. (2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist.
    Pasquinucci L; Turnaturi R; Calò G; Pappalardo F; Ferrari F; Russo G; Arena E; Montenegro L; Chiechio S; Prezzavento O; Parenti C
    Eur J Med Chem; 2019 Apr; 168():189-198. PubMed ID: 30822708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel
    Turnaturi R; Chiechio S; Pasquinucci L; Spoto S; Costanzo G; Dichiara M; Piana S; Grasso M; Amata E; Marrazzo A; Parenti C
    Molecules; 2022 Aug; 27(16):. PubMed ID: 36014375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation.
    Pasquinucci L; Turnaturi R; Montenegro L; Caraci F; Chiechio S; Parenti C
    Eur J Pharmacol; 2019 Mar; 847():97-102. PubMed ID: 30690004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands.
    Costanzo G; Patamia V; Turnaturi R; Parenti C; Zagni C; Lombino J; Amata E; Marrazzo A; Pasquinucci L; Rescifina A
    Chem Biol Drug Des; 2023 Jun; 101(6):1382-1392. PubMed ID: 36813756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of N-substituent structural variations in opioid receptor profile of LP1.
    Pasquinucci L; Turnaturi R; Aricò G; Parenti C; Pallaki P; Georgoussi Z; Ronsisvalle S
    Bioorg Med Chem; 2016 Jun; 24(12):2832-42. PubMed ID: 27234885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment.
    Pasquinucci L; Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Georgoussi Z; Fourla DD; Scoto GM; Ronsisvalle G
    Life Sci; 2012 Jan; 90(1-2):66-70. PubMed ID: 22100511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of novel LP1-based analogues with enhanced delta opioid receptor profile.
    Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C
    Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain.
    Ronsisvalle S; Aricò G; Panarello F; Spadaro A; Pasquinucci L; Pappalardo MS; Parenti C; Ronsisvalle N
    Bioorg Med Chem; 2016 Nov; 24(21):5280-5290. PubMed ID: 27624520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists.
    Turnaturi R; Parenti C; Prezzavento O; Marrazzo A; Pallaki P; Georgoussi Z; Amata E; Pasquinucci L
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29547588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LP1 and LP2: Dual-Target MOPr/DOPr Ligands as Drug Candidates for Persistent Pain Relief.
    Pasquinucci L; Parenti C; Georgoussi Z; Reina L; Tomarchio E; Turnaturi R
    Molecules; 2021 Jul; 26(14):. PubMed ID: 34299443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand.
    Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L
    Life Sci; 2012 Jun; 90(25-26):957-61. PubMed ID: 22580287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in the development of more effective and safer analgesics for pain management.
    Turnaturi R; Chiechio S; Salerno L; Rescifina A; Pittalà V; Cantarella G; Tomarchio E; Parenti C; Pasquinucci L
    Eur J Med Chem; 2019 Dec; 183():111701. PubMed ID: 31550662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.
    Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI
    ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploiting the Power of Stereochemistry in Drug Action: 3-[(2
    Turnaturi R; Pasquinucci L; Chiechio S; Grasso M; Marrazzo A; Amata E; Dichiara M; Prezzavento O; Parenti C
    ACS Chem Neurosci; 2020 Apr; 11(7):999-1005. PubMed ID: 32186844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors.
    Eans SO; Ganno ML; Mizrachi E; Houghten RA; Dooley CT; McLaughlin JP; Nefzi A
    J Med Chem; 2015 Jun; 58(12):4905-17. PubMed ID: 25996309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures.
    Parenti C; Turnaturi R; Aricò G; Gramowski-Voss A; Schroeder OH; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L
    Neuropharmacology; 2013 Aug; 71():70-82. PubMed ID: 23541722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluations of novel endomorphin analogues containing α-hydroxy-β-phenylalanine (AHPBA) displaying mixed μ/δ opioid receptor agonist and δ opioid receptor antagonist activities.
    Hu M; Giulianotti MA; McLaughlin JP; Shao J; Debevec G; Maida LE; Geer P; Cazares M; Misler J; Li L; Dooley C; Ganno ML; Eans SO; Mizrachi E; Santos RG; Yongye AB; Houghten RA; Yu Y
    Eur J Med Chem; 2015 Mar; 92():270-81. PubMed ID: 25559207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
    Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and in vitro and in vivo activity of (-)-(1R,5R,9R)- and (+)-(1S,5S,9S)-N-alkenyl-, -N-alkynyl-, and -N-cyanoalkyl-5, 9-dimethyl-2'-hydroxy-6,7-benzomorphan homologues.
    May EL; Jacobson AE; Mattson MV; Traynor JR; Woods JH; Harris LS; Bowman ER; Aceto MD
    J Med Chem; 2000 Dec; 43(26):5030-6. PubMed ID: 11150174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice.
    Yang PP; Yeh GC; Yeh TK; Xi J; Loh HH; Law PY; Tao PL
    Pharmacol Res; 2016 Sep; 111():867-876. PubMed ID: 27496654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.